TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Matthew J Ellis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.